Cure Interviews Brett Pletcher in "Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines"

Gunderson Dettmer life sciences and public companies advisor Brett Pletcher was featured in Cure's article, "Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines," which discusses how technology transfer works in biotech and pharma, the different types of transfers, and why poor execution can delay commercialization.

Depending on the stage of development when a tech transfer occurs, the process can range from relatively straightforward to highly complex. “If a discovery platform is licensed out, that process is pretty easy," Brett explained. "The licensor hands over the assays or other discovery technologies, explains how to make and use them, and the parties go on their merry way. The further along the drug gets, the more complicated the tech transfer becomes.”

Read the full article here.